Rheum Round-up: CEO of Flexion Therapeutics on Developing MSK Therapies, Risk Factors for Radiographic OA Progression, and more

DocWire News with spoke with Mike Clayman, MD, CEO at Flexion Therapeutics, a company focused on the development of novel, local therapies for the treatment of musculoskeletal (MSK) conditions – with one approved drug – ZILRETTA® for osteoarthritis (OA) knee pain. See what Dr. Clayman had to say about these therapies.

Patients with mild radiographic OA of the knee who use non-steroidal anti-inflammatory drugs (NSAIDs) and do not meet physical activity guidelines are at risk of radiographic progression, according to a study. Overall, 58 patients (12%) sustained radiographic OA progression. Univariate analysis identified NSAID use, inadequate physical activity, and high baseline pain as clinical factors eligible for inclusion in the multivariable model.

A study observed a correlation between patients’ expectations toward newly induced disease-modifying antirheumatic drug therapies and clinical response among patients with rheumatoid arthritis.

Finally, a review published in RMD Open discussed the literature currently available regarding intra-articular therapies (IAT) for autoimmune and rheumatic diseases.

 

In Case You Missed It:

Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal Disorders

Researchers Identify Risk Factors for Radiographic Progression of Osteoarthritis of the Knee

Could Patients’ Expectations Impact Clinical Response to DMARDs in Rheumatoid Arthritis?

An Analysis of Currently Available Data on Intra-Articular Therapies in Rheumatic Disease